MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.79
+0.20
+1.39%
Opening 13:29 02/24 EST
OPEN
14.72
PREV CLOSE
14.59
HIGH
14.93
LOW
14.51
VOLUME
660.68K
TURNOVER
--
52 WEEK HIGH
29.61
52 WEEK LOW
13.39
MARKET CAP
1.09B
P/E (TTM)
-5.4111
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China
Benzinga · 6h ago
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
and , /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology...
PR Newswire - PRF · 18h ago
The EVP, Chief Dev. Officer of Karyopharm Therapeutics (KPTI) is Selling Shares
Yesterday, the EVP, Chief Dev. Officer of Karyopharm Therapeutics (KPTI), Ran Frenkel, sold shares of KPTI for $42.81K. In addition to Ran Frenkel, 5
SmarterAnalyst · 1d ago
What Did This CEO Just Do with Personal Shares of Karyopharm Therapeutics (KPTI)?
Yesterday, the CEO of Karyopharm Therapeutics (KPTI), Michael Kauffman, sold shares of KPTI for $281.6K. In addition to Michael Kauffman, 5 other KPTI
SmarterAnalyst · 1d ago
The President & CSO of Karyopharm Therapeutics (KPTI) is Selling Shares
Yesterday, the President & CSO of Karyopharm Therapeutics (KPTI), Sharon Shacham, sold shares of KPTI for $281.6K. In addition to Sharon Shacham, 5
SmarterAnalyst · 1d ago
Veterinary Oncology Market Size, Sales Revenue, 2021-2029 , Top Keyplayers – PetCure Oncology, Nippon Zenyaku Kogyo Co., Ltd. etc.
Veterinary Oncology Market 2021 Feb 22, 2021 (Market Insight Reports) -- Straits Research Market report Provides detailed analysis of the Veterinary Oncology...
Market Insight Reports · 2d ago
Leiomyosarcoma Drug Market Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 06:06:28 / Comserve Inc. / -- Leiomyosarcoma Drug market is segmented by Type, and by Application. Players, stakeholders, and...
Comserve · 2d ago
Nicotinamide Phosphoribosyl Transferase Market Classification, Opportunities, Types and Applications, Status and Forecast 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 06:01:37 / Comserve Inc. / -- Nicotinamide Phosphoribosyl Transferase market is segmented by Type, and by Application. Players,...
Comserve · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KPTI. Analyze the recent business situations of Karyopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KPTI stock price target is 30.00 with a high estimate of 49.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 270
Institutional Holdings: 74.04M
% Owned: 100.60%
Shares Outstanding: 73.60M
TypeInstitutionsShares
Increased
58
8.11M
New
48
-5.30M
Decreased
44
6.50M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.24%
Pharmaceuticals & Medical Research
+1.33%
Key Executives
President/Chief Scientific Officer
Sharon Shacham
Chief Executive Officer/Co-Founder/Director
Michael Kauffman
Chief Financial Officer/Senior Vice President/Treasurer
Michael Mason
Executive Vice President/General Counsel/Secretary
Christopher Primiano
Executive Vice President
Tanya Lewis
Executive Vice President
Jatin Shah
Senior Vice President/Director of Sales
Perry Monaco
Other
Ran Frenkel
Other
Stephen Mitchener
Lead Director/Independent Director
Barry Greene
Director
Mansoor Mirza
Director
Christy Oliger
Independent Director
Deepika Pakianathan
Director
Chen Schor
Independent Director
Garen Bohlin
Independent Director
Mikael Dolsten
Independent Director
Deepa Pakianathan
Independent Director
Richard Paulson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About KPTI
Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.